Local Chemoarchitecture Explains Widespread Lower Cortical Thickness Associated with Clinical High Risk for Psychosis

Why It Matters

Understanding the neurochemical drivers of cortical thinning could improve early detection and guide targeted interventions for psychosis risk populations.

Key Takeaways

• CHR individuals show diffuse cortical thinning
• Receptor density predicts regional thickness loss
• Chemoarchitecture offers mechanistic insight
• Open code enables replication and extension
• Findings may inform early therapeutic strategies

Pulse Analysis

The transition from prodromal symptoms to full‑blown psychosis has long challenged clinicians, prompting a search for reliable biomarkers. Cortical thickness, measurable via high‑resolution MRI, consistently appears reduced in patients with schizophrenia and, to a lesser extent, in those identified as clinical high risk. Prior meta‑analyses highlighted this thinning but left its biological underpinnings ambiguous, limiting its utility for early diagnosis.

The current investigation bridges that gap by overlaying cortical thickness maps with region‑specific neurotransmitter receptor atlases. Using multilinear regression and dominance analysis, the authors demonstrated that areas rich in excitatory glutamate receptors and deficient in inhibitory GABAergic markers correspond to the most pronounced thinning in CHR cohorts. This chemoarchitectural fingerprint not only explains the spatial pattern of atrophy but also aligns with earlier ENIGMA mega‑analyses linking receptor distribution to psychosis onset. By making both the imaging pipelines and statistical scripts publicly accessible, the study invites validation across larger, multi‑site datasets.

These insights carry practical implications. If specific receptor profiles forecast cortical loss, they could become targets for pharmacological modulation, potentially halting or reversing neurodegeneration before psychosis manifests. Moreover, integrating chemoarchitectural data into risk‑assessment algorithms may sharpen predictive accuracy, aiding clinicians in allocating preventive resources. Future work will likely explore longitudinal changes, test receptor‑focused interventions, and expand the framework to other neuropsychiatric disorders where cortical morphology and neurotransmission intersect.